A multicenter, open-ended, noninterventive registry study of patients with chronic subdural hematoma was conducted to evaluate the clinical characteristics of chronic subdural hematoma in Chinese and the efficacy and safety of atorvastatin calcium in the treatment of chronic subdural hematoma in neurosurgical clinical practice

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057179

Enrollment

Unknown

Registered

2022-03-02

Start date

2022-03-11

Completion date

Unknown

Last updated

2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic subdural Hematoma

Interventions

Surgery group:None

Drug group:None

Eligibility

Sex/Gender

All

Age

No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. No age limit; 2. No gender limit; 3. Disease: patients diagnosed with chronic subdural hematoma based on CT or magnetic resonance imaging combined with clinical signs and symptoms; 4. Serial and sequential registration of all eligible patients with chronic subdural hematoma.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Modified Rankin Scale (mRS) Score;	—

Secondary

Measure	Time frame
Recurrence rate;Mortality;Hematoma volume;	—

Countries

China

Contacts

Public ContactJiang Rongcai

Tianjin Medical University General Hospital

jiang116216@163.com+86 136 7211 6556

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026